Alterity Therapeutics (ATHE) Competitors $5.40 +0.19 (+3.65%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$5.35 -0.05 (-0.93%) As of 08/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. DSGN, LIMN, VTYX, RAPT, MDWD, TLSA, ELDN, DMAC, YMAB, and NLTXShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Design Therapeutics (DSGN), Liminatus Pharma (LIMN), Ventyx Biosciences (VTYX), Rapt Therapeutics (RAPT), MediWound (MDWD), Tiziana Life Sciences (TLSA), Eledon Pharmaceuticals (ELDN), DiaMedica Therapeutics (DMAC), Y-mAbs Therapeutics (YMAB), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors Design Therapeutics Liminatus Pharma Ventyx Biosciences Rapt Therapeutics MediWound Tiziana Life Sciences Eledon Pharmaceuticals DiaMedica Therapeutics Y-mAbs Therapeutics Neoleukin Therapeutics Design Therapeutics (NASDAQ:DSGN) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment. Is DSGN or ATHE more profitable? Alterity Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -22.85% -22.02% Alterity Therapeutics N/A N/A N/A Which has more volatility and risk, DSGN or ATHE? Design Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Do analysts rate DSGN or ATHE? Alterity Therapeutics has a consensus target price of $12.00, indicating a potential upside of 122.22%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders have more ownership in DSGN or ATHE? 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, DSGN or ATHE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$0.99-4.10Alterity TherapeuticsN/AN/A-$12.54MN/AN/A Does the media refer more to DSGN or ATHE? In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Design Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAlterity Therapeutics beats Design Therapeutics on 7 of the 9 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.20M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.73%4.14%P/E RatioN/A17.5328.9123.88Price / SalesN/A313.17445.5998.82Price / CashN/A42.6035.6858.35Price / Book5.197.828.165.60Net Income-$12.54M-$54.52M$3.25B$265.26M7 Day Performance4.45%2.86%1.17%-0.14%1 Month Performance33.83%17.29%8.27%6.08%1 Year Performance332.00%13.27%29.19%24.22% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics1.7516 of 5 stars$5.40+3.6%$12.00+122.2%+350.0%$46.20MN/A0.0010Gap DownDSGNDesign Therapeutics0.325 of 5 stars$4.04+0.5%$4.00-1.0%-12.9%$228.21MN/A-4.0840LIMNLiminatus PharmaN/A$8.08-7.2%N/AN/A$226.59MN/A0.00N/AVTYXVentyx Biosciences2.7973 of 5 stars$3.04-4.4%$10.00+228.9%+27.7%$226.29MN/A-1.7430RAPTRapt Therapeutics4.0383 of 5 stars$12.67-4.8%$21.67+71.0%-53.4%$220.09MN/A-0.6680MDWDMediWound2.2161 of 5 stars$19.93-2.0%$32.25+61.8%+9.8%$219.72M$20.22M-9.5480Upcoming EarningsTLSATiziana Life Sciences0.8794 of 5 stars$1.95+4.8%N/A+124.5%$217.34MN/A0.008Positive NewsELDNEledon Pharmaceuticals1.697 of 5 stars$3.23-10.8%$10.00+209.6%+16.4%$216.77MN/A-1.5410High Trading VolumeDMACDiaMedica Therapeutics1.4623 of 5 stars$5.06+0.2%$10.75+112.5%+30.1%$216.56MN/A-7.9120YMABY-mAbs Therapeutics2.9985 of 5 stars$4.88+2.3%$15.60+219.7%-20.8%$216M$87.68M-7.63150News CoverageUpcoming EarningsAnalyst ForecastGap UpNLTXNeoleukin TherapeuticsN/A$22.72-0.4%N/A-45.1%$213.52MN/A-7.3190 Related Companies and Tools Related Companies DSGN Competitors LIMN Competitors VTYX Competitors RAPT Competitors MDWD Competitors TLSA Competitors ELDN Competitors DMAC Competitors YMAB Competitors NLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHE Stock Alerts